title: Screening of telomerase inhibitors.
abstract: Shortening of telomeres prevents cells from uncontrolled proliferation. Progressive telomere shortening occurs at each cell division until a critical telomeric length is reached. Telomerase expression is switched off after embryonic differentiation in most normal cells, but it is expressed in a very high percentage of tumors of different origin. Thus, telomerase is regarded as the best tumor marker and a promising novel molecular target for cancer treatment. Therefore, different strategies to inhibit telomerase have been developed. However, systematic screening of telomerase inhibitors has not been performed to compare their therapeutic potential. We propose a suitable strategy for estimation of the therapeutic potential of telomerase inhibitors, which is based on a systematic screening of different inhibitors in the same cell system. From the long list of compounds discussed in the literature, we have selected four telomerase inhibitors of different structure and mode of action: BRACO19 (G-quadruplex-interactive compound), BIBR1532 (non-nucleosidic reverse transcriptase inhibitor), 2'-O-methyl RNA, and peptide nucleic acids (PNAs; hTR antisense oligonucleotides). To determine minimal effective concentrations for telomerase inhibition, telomerase activity was measured using the cell-free telomerase repeat amplification protocol (TRAP) assay. We also tested inhibitors in long-term cell-culture experiments by exposing A-549 cells to non-cytotoxic concentrations of inhibitors for a period of 99 days. Subsequently, telomerase activity of A-549 cells was investigated using the TRAP assay, and telomere length of samples was assessed by telomere restriction fragment (TRF) Southern blot analysis.
authors: Dr Margarete Fiscer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
authors: Elke
authors: E
authors: Kleideiter
authors: Kamilla
authors: K
authors: Piotrowska
authors: Ulrich
authors: U
authors: Klotz
mesh_terms: D000166:Acridines / Q000737:chemistry / Q000494:pharmacology; D062365:Aminobenzoates / Q000737:chemistry / Q000494:pharmacology; D001973:Bromodeoxyuridine / Q000378:metabolism; D045744:Cell Line, Tumor; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004791:Enzyme Inhibitors / Q000032:analysis* / Q000494:pharmacology*; D006801:Humans; D009281:Naphthalenes / Q000737:chemistry / Q000494:pharmacology; D021141:Nucleic Acid Amplification Techniques; D019098:Telomerase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016615:Telomere / Q000378:metabolism; D013997:Time Factors
chemical_list: D000166:Acridines; D062365:Aminobenzoates; C458523:BIBR 1532; D004791:Enzyme Inhibitors; D009281:Naphthalenes; C509186:TERT protein, human; D019098:Telomerase; D001973:Bromodeoxyuridine; C454064:BRACO-19